KGKomal Gupta

Komal Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Komal Gupta has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rethinking Molecular Profiling after First-line Osimertinib

    by Komal Gupta, Daniel S.W. Tan, Regina Hoo

    Summary: A recent article presents the largest histogenomic characterization of first-line osimertinib resistance from the ORCHARD study. Dual-modality tissue and plasma sequencing detected resistance alterations in 87% of patients and polyclonal mechanisms in 46% of patients, highlighting the complexity of post-osimertinib biology and raising questions about targeted versus broadly acting regimens in the post-EGFR tyrosine kinase inhibitor setting. See related article by Yu et al., p. 3746


  • Open Access

    CRISPR/Cas9 targeting of MCPyV T antigen in Merkel tumors

    by Reety Arora, Komal Gupta, Anjali Vijaykumar

    Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer caused either by Merkel cell polyomavirus (MCPyV) T antigen gene expression, post integration (∼80% cases), or by UV mediated DNA damage. Viral-positive Merkel tumors are not only caused by but also oncogenically addicted to tumor antigen expression. In this study we used CRISPR-Cas9 based gene-editing to develop a potential therapeutic tool for MCPyV positive MCC. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system is a genome editing technology whereby a guide RNA (gRNA) molecule, targets a Cas endonuclease to a specific genomic site, using sequence homology, and induces a double strand break. To target MCPyV T antigens, we designed a strategy using 2 gRNAs targeting the T antigen genomic region that would cut off a substantial portion of the gene thereby rendering it dysfunctional. We validated the MCPYV T antigen targeting efficiency of our gRNAs, both individually and together by in vitro cleavage assays. Finally, to translate this finding, we delivered this CRISPR system in patient-derived MCC cell lines and show reduction in T antigen gene expression. Our proof-of-concept study shows that 2 MCPyV targeting CRISPR/Cas gRNAs in combination can knock out MCPyV T antigen, thus, being of therapeutic importance. We hope that this CRISPR system can be potentially delivered in vivo for advancing MCPyV positive MCC treatment in the future.